Isoprinosine

Inosine Pranobex, the active ingredient in Isoprinosine, is an immunomodulator presented as an oral dosage form for oral use. It is employed to support the immune response in viral infections such as herpes simplex, influenza, and in certain immunodeficiency conditions. It is indicated for acute viral illnesses and for patients with compromised immunity, offering a broad antiviral effect through immune stimulation.

GNH USA supplies Isoprinosine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory support for global health institutions.

Isoprinosine (inosine pranobex) acts as an immunomodulatory antiviral, targeting a range of viral infections and immune‑deficient states. - Herpes simplex infections: reduces lesion duration and viral shedding by enhancing host immunity. - Influenza and other acute viral infections: shortens illness course and alleviates symptoms through immune stimulation. - Subacute sclerosing panencephalitis (SSPE): may slow disease progression by supporting antiviral defenses. - Immunodeficiency states: helps improve immune function and resistance to opportunistic infections.

Inosine pranobex is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Rash: skin erythema or mild itching. - Elevated liver enzymes: mild, reversible changes in hepatic function tests.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Hematologic abnormalities: thrombocytopenia or leukopenia. - Hepatotoxicity: significant liver injury with jaundice. - Cardiac arrhythmias: rare cases of rhythm disturbances.

When prescribing or dispensing Isoprinosine, consider the following precautions to ensure safe use. - Pregnancy: safety has not been established; avoid use unless benefits outweigh risks. - Breastfeeding: unknown excretion; caution advised for nursing mothers. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic dysfunction: monitor liver enzymes regularly. - Immunocompromised patients: assess risk‑benefit as immune stimulation may affect disease course. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Inosine pranobex may interact with other medicines; awareness of key interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may counteract immunostimulatory effect. - Live vaccines: increased risk of uncontrolled infection due to immune modulation. - Antiviral agents (e.g., acyclovir) with overlapping toxicity: potential additive hepatic stress.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): possible alteration of INR, monitor coagulation. - Antihypertensives: may affect blood pressure control, observe vitals. - CNS depressants: potential enhanced sedation, adjust dosing if needed.